• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Brompton Lifeco Split Corp Class A
DEFSEC Technologies Inc. - common stock, no R/S concurrent with offering
Kasikornbank Pcl ADR
Latin Metals Inc
Planet Green Holdings Corp. Common Stock
SBC Medical Group Holdings Incorporated - Common Stock
Tourmaline Bio, Inc. - Common Stock
Twinlab Consolidated Holdings Inc
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

51.30 -2.91 (-5.37%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56,035
Open 54.15
Bid (Size) 47.00 (100)
Ask (Size) 56.21 (100)
Prev. Close 54.21
Today's Range 51.30 - 54.15
52wk Range 47.23 - 123.75
Shares Outstanding 11,834,361
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
September 30, 2026
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
May 26, 2026
From Bright Minds Biosciences
Via GlobeNewswire

Performance

52-Week Range 58.5% below 52-week high
51.30
47.2352W Low 123.7552W High
1 Week 8.0% below 1-week high
49.061W Low 55.751W High

Bright Minds Biosciences Inc. - common stock (DRUG) traded between $47.23 and $123.75 over the past 52 weeks and last traded at $51.30, 58.5% below its 52-week high. Over the past week it ranged between $49.06 and $55.75.

Past 12 Months
-5.0%
-13.2%
-32.6%
-42.9%
-38.5%
-22.7%
1W -$2.71
1M -$7.81
3M -$24.82
6M -$38.60
YTD -$32.16
1Y -$15.10

DRUG was -22.7% over the past year, -42.9% over six months, -38.5% year to date, -5.0% in the last week.

12 Months vs Market
DRUG
-22.7%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months DRUG returned -22.7% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.39× 3-mo avg
Today 56,035 3-mo avg 145.2K
1W
151.6K
1M
141.8K
3M
145.2K
6M
226.9K
YTD
206.5K
1Y
199.8K

DRUG most recently traded 56,035 shares against a 3-month average daily volume of 145.2K.

More News

Read More
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
May 26, 2026
Via The Motley Fool
Topics Regulatory Compliance Stocks
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
May 21, 2026
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
May 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
Via MarketMinute
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
January 09, 2026
From Bright Minds Biosciences
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
January 07, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
January 06, 2026
Via Chartmill
News headline image
Why Did DRUG Stock Rocket 51% Today? ↗
January 06, 2026
Via Stocktwits
Stay updated with the stocks that are on the move in today's pre-market session. ↗
January 06, 2026
Via Chartmill
News headline image
Why Bright Minds Biosciences Stock Topped the Market on Monday ↗
November 17, 2025
Via The Motley Fool
News headline image
Large Patient Population Is Key Driver For Bright Minds' Growth ↗
September 08, 2025
Via Benzinga
News headline image
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗
May 07, 2025
Via Benzinga
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
March 04, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
February 24, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Biotechs on the Brink: 2 Stocks With Huge Potential
February 14, 2025
Via MarketBeat
News headline image
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
January 23, 2025
Via Benzinga
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
January 07, 2025
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
November 21, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗
November 13, 2024
Via The Motley Fool
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
November 04, 2024
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
November 04, 2024
Via Benzinga
Topics Government
News headline image
What's Going On With Bright Minds Biosciences Stock? ↗
October 21, 2024
Via Benzinga
Topics Artificial Intelligence
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
October 21, 2024
From Bright Minds Biosciences
Via GlobeNewswire

Frequently Asked Questions

Is Bright Minds Biosciences Inc. - common stock publicly traded?
Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.
What exchange does Bright Minds Biosciences Inc. - common stock trade on?
Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?
The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market
What is the current price of Bright Minds Biosciences Inc. - common stock?
The current price of Bright Minds Biosciences Inc. - common stock is 51.30
When was Bright Minds Biosciences Inc. - common stock last traded?
The last trade of Bright Minds Biosciences Inc. - common stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Bright Minds Biosciences Inc. - common stock?
The market capitalization of Bright Minds Biosciences Inc. - common stock is 607.10M
How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?
Bright Minds Biosciences Inc. - common stock has 607M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap